By Daniella Parra
Vaxxinity, Inc. (Nasdaq: VAXX) said early clinical data demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease for its UB-311 vaccine.
The Phase 2a study, conducted in Taiwan showed that UB-311 offers advantages such as lower ARIA-E rates, convenient dosing via intramuscular injection, and cost-effectiveness, the company said in a statement. Co-author Dr. Jeffrey Cummings noted UB-311’s safety and potential for transforming Alzheimer’s treatment.
“This publication supports the innovative work that we and our collaborators are conducting to advance UB-311 for the potential treatment, and even prevention, of Alzheimer’s disease,” said Mei Mei Hu, CEO of Vaxxinity. “Imagine expanding the addressable patient population of beta-amyloid immunotherapies by multiple orders of magnitude, potentially over 1,000x, and delivering life-changing medicine at a fraction of the cost. That is our vision for UB-311 and the potential power of active immunotherapies.”